Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance in Ovarian Cancer

ABSTRACT: Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance in Ovarian Cancer

PROVIDER: PRJNA932806 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23374126_1.fastq.gz	Fastqsanger.gz
	SRR23374126_2.fastq.gz	Fastqsanger.gz
	SRR23374127_1.fastq.gz	Fastqsanger.gz
	SRR23374127_2.fastq.gz	Fastqsanger.gz
	SRR23374128_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance

Project description:Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance

| PRJNA879768 | ENA

Tumor intrinsic METTL5 induces immune resistance in ovarian cancer by suppressing ferroptosis

Project description:Despite approval of immunotherapy for the treatment of ovarian cancer patients, the majority of patients fail to respond to immunotherapy or relapse following initial response. These failures may be attributed to immunosuppressive mechanisms co-opted by tumor cells. However, it is challenging to use conventional methods to systematically evaluate the potential of tumor intrinsic factors to act as immune regulators in patients with cancer. To identify immunosuppressive mechanisms in non-responders to cancer immunotherapy in ovarian cancer , we firstly performed an unbiased genome-wide CRISPR immune screens to explore tumor intrinsic factors which regulates ovarian cancer cell lines response to T cell mediated killing. Then we integrated the in vitro CRISPR screen results with multi-omics clinical data to generate a sub-library including top candidates for in vivo CRISPR screen to further evaluate the role of potential tumor intrinsic factors in regulating ovarian cancer cell response to immunotherapy with using the immune checkpoint blocker. Collectively, the data provide a rich resource of novel targets for rational immuno-oncology combinations.

2025-10-30 | GSE267542 | GEO

Tumor cell-intrinsic Decr2 regulates ferroptosis and immunotherapy efficacy

Project description:Tumor cell-intrinsic Decr2 regulates ferroptosis and immunotherapy efficacy

| PRJNA1200063 | ENA

Tumor cell-intrinsic Decr2 is necessary for immunotherapy efficacy

Project description:Tumor cell-intrinsic Decr2 is necessary for immunotherapy efficacy

| PRJEB75776 | ENA

Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer

Project description:Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer

| PRJNA754392 | ENA

Tumor-intrinsic ST3GAL3 Activity Blunts Anti-tumor Immune and Drives Immunotherapy Resistance in Ovarian Cancer

Project description:ST3GAL3 is a α2,3-sialyltransferase and involves in α2,3 sialylation in tumors; however, its role in the tumorigenic capacity of malignant cells and anti-tumor immune remains largely unexplored. Here, HM1 cells were stably transfected using lentivirus expressing a shRNA targeting ST3GAL3 (HM1-shST3GAL3) or scramble shRNA as control (HM1-shControl). Then, HM1-shControl or HM1-shST3GAL3 cells were injected into the right flank of B6C3F1 mice using a 27 g needle. ST3GAL3 knockdown significantly compromised tumor growth at a immune-dependant manner. Mechanistically, ST3GAL3 knockdown enhances pro-inflammatory phenotype of macrophages, leading ultimately to activation and recruitmentof CD8+ T cells. Moreover, we identified ST3GAL3 as a potential novel biomarker for bevacizumab or immune checkpoint blockade (ICB) intervention. ST3GAL3 knockdown in tumors also be useful to improve cancer immunotherapies.

2023-05-09 | GSE224856 | GEO

Targeting tumor-intrinsic S100A1 augments antitumor immunity and potentiates immunotherapy efficacy

Project description:Targeting tumor-intrinsic S100A1 augments antitumor immunity and potentiates immunotherapy efficacy

| PRJNA1205386 | ENA

BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

Project description:BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

| PRJNA913003 | ENA

Targeting tumor-intrinsic S100A1 augments antitumor immunity and potentiates immunotherapy efficacy

Project description:Immune checkpoint blockade (ICB) has revolutionized cancer treatment, but the therapeutic response is highly heterogeneous. A potential mode of resistance is tumor-intrinsic mechanisms leading to an immunosuppressive tumor microenvironment. However, the underlying interactive network remains elusive and the generalizable biomarkers and targeting strategies are still lacking. Here, we uncovered the potential of plasma S100 calcium-binding protein A1 (S100A1) in determining ICB efficacy based on liquid biopsy of patients with lung cancer. Muti-omics and functional studies suggested that tumor-intrinsic S100A1 expression correlates with an immunologically cold TME and resistance to ICB. Mechanistic investigations demonstrated that interfering with tumor-intrinsic S100A1/ubiquitin-specific protease 7/p65/granulocyte-macrophage colony-stimulating factor (GM-CSF) modulatory axis could potentiate an inflamed TME via promoting M1-like macrophage polarization and T cell function. GM-CSF priming was sufficient to enhance ICB response in tumors with high S100A1 expression. These findings defined S100A1 as a potential biomarker and a novel synergistic target for cancer immunotherapy.

2025-03-26 | GSE285657 | GEO

Systematic identification of tumor-intrinsic resistance mechanisms and combinatorial therapy targets for immunotherapy

Project description:A number of reports have demonstrated that tumor-intrinsic mechanisms of resistance, such as the loss of genes critical for antigen presentation and inflammatory responses, along with the activation of various cellular signaling cascades, can limit the efficacy of immunotherapy. Strategies to sensitize tumor cells to immunotherapy may overcome some resistance mechanisms, but identifying therapeutic targets has remained challenging. Here, we integrate a two-cell type (2CT) whole-genome CRISPR-Cas9 screen with dynamic transcriptional profiling of the tumor/T cell interaction to comprehensively identify tumor genes that are induced to promote tumor survival. We assessed the therapeutic potential of pharmacological inhibition of these and other top CRISPR identified targets as combinatorial targets to improve the efficacy of tumor destruction by T cells.

2022-08-31 | GSE137824 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data